KRAS and neoplasm: In pancreatic cancer, the signature genetic mutational landscape of over 90% of Kras oncogene mutations plays a critical role in controlling tumor metabolism by enhancing glucose uptake, accelerating glycolytic flux, and increasing lactate production and fuelling cancer progression.65, 66